tetano
Editor, Senior Moderator
Cells
. 2020 Jun 30;9(7):E1583.
doi: 10.3390/cells9071583.
Vasculopathy and Coagulopathy Associated With SARS-CoV-2 Infection
Nazzarena Lab?[SUP] 1 [/SUP], Hidetaka Ohnuki[SUP] 2 [/SUP], Giovanna Tosato[SUP] 2 [/SUP]
Affiliations
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in > 500,000 deaths worldwide, including > 125,000 deaths in the U.S. since its emergence in late December 2019 and June 2020. Neither curative anti-viral drugs nor a protective vaccine is currently available for the treatment and prevention of COVID-19. Recently, new clinical syndromes associated with coagulopathy and vasculopathy have emerged as a cause of sudden death and other serious clinical manifestations in younger patients infected with SARS-CoV-2 infection. Angiotensin converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 and other coronaviruses, is a transmembrane protein expressed by lung alveolar epithelial cells, enterocytes, and vascular endothelial cells, whose physiologic role is to induce the maturation of angiotensin I to generate angiotensin 1-7, a peptide hormone that controls vasoconstriction and blood pressure. In this review, we provide the general context of the molecular and cellular mechanisms of SARS-CoV-2 infection with a focus on endothelial cells, describe the vasculopathy and coagulopathy syndromes in patients with SARS-CoV-2, and outline current understanding of the underlying mechanistic aspects.
Keywords: ACE2; COVID-19; SARS-CoV-2; inflammatory cytokines; vascular inflammation; vasculopathy.
. 2020 Jun 30;9(7):E1583.
doi: 10.3390/cells9071583.
Vasculopathy and Coagulopathy Associated With SARS-CoV-2 Infection
Nazzarena Lab?[SUP] 1 [/SUP], Hidetaka Ohnuki[SUP] 2 [/SUP], Giovanna Tosato[SUP] 2 [/SUP]
Affiliations
- PMID: 32629875
- DOI: 10.3390/cells9071583
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), has resulted in > 500,000 deaths worldwide, including > 125,000 deaths in the U.S. since its emergence in late December 2019 and June 2020. Neither curative anti-viral drugs nor a protective vaccine is currently available for the treatment and prevention of COVID-19. Recently, new clinical syndromes associated with coagulopathy and vasculopathy have emerged as a cause of sudden death and other serious clinical manifestations in younger patients infected with SARS-CoV-2 infection. Angiotensin converting enzyme 2 (ACE2), the receptor for SARS-CoV-2 and other coronaviruses, is a transmembrane protein expressed by lung alveolar epithelial cells, enterocytes, and vascular endothelial cells, whose physiologic role is to induce the maturation of angiotensin I to generate angiotensin 1-7, a peptide hormone that controls vasoconstriction and blood pressure. In this review, we provide the general context of the molecular and cellular mechanisms of SARS-CoV-2 infection with a focus on endothelial cells, describe the vasculopathy and coagulopathy syndromes in patients with SARS-CoV-2, and outline current understanding of the underlying mechanistic aspects.
Keywords: ACE2; COVID-19; SARS-CoV-2; inflammatory cytokines; vascular inflammation; vasculopathy.